BR112018011177A2 - conjugados de citarabina para terapia de câncer - Google Patents

conjugados de citarabina para terapia de câncer

Info

Publication number
BR112018011177A2
BR112018011177A2 BR112018011177A BR112018011177A BR112018011177A2 BR 112018011177 A2 BR112018011177 A2 BR 112018011177A2 BR 112018011177 A BR112018011177 A BR 112018011177A BR 112018011177 A BR112018011177 A BR 112018011177A BR 112018011177 A2 BR112018011177 A2 BR 112018011177A2
Authority
BR
Brazil
Prior art keywords
cancer therapy
cytarabine
conjugates
cytarabine conjugates
relates
Prior art date
Application number
BR112018011177A
Other languages
English (en)
Inventor
Ben Yakar Ruth
Gengrinovitch Stela
Original Assignee
Biosight Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosight Ltd filed Critical Biosight Ltd
Publication of BR112018011177A2 publication Critical patent/BR112018011177A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

a presente invenção se refere a conjugados compreendendo citarabina e um aminoácido para uso no tratamento de câncer. em particular, a presente invenção se refere a conjugados de citarabina e ácido aspártico para uso no tratamento de cânceres hematológicos em pacientes clinicamente comprometidos.
BR112018011177A 2015-12-03 2016-01-25 conjugados de citarabina para terapia de câncer BR112018011177A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562262428P 2015-12-03 2015-12-03
PCT/IL2016/050077 WO2017093993A1 (en) 2015-12-03 2016-01-25 Cytarabine conjugates for cancer therapy

Publications (1)

Publication Number Publication Date
BR112018011177A2 true BR112018011177A2 (pt) 2018-11-21

Family

ID=58796462

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018011177A BR112018011177A2 (pt) 2015-12-03 2016-01-25 conjugados de citarabina para terapia de câncer

Country Status (10)

Country Link
US (1) US11058701B2 (pt)
EP (1) EP3383407B1 (pt)
JP (3) JP7149183B2 (pt)
CN (1) CN108289905A (pt)
AU (2) AU2016362830B2 (pt)
BR (1) BR112018011177A2 (pt)
CA (1) CA3007058C (pt)
IL (2) IL259631B (pt)
RU (1) RU2708672C1 (pt)
WO (1) WO2017093993A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018535987A (ja) 2015-12-03 2018-12-06 バイオサイト リミテッド 癌療法のためのコンジュゲートの塩
IL271946B (en) * 2017-07-09 2022-09-01 Biosight Ltd Combination for cancer treatment
CN110590862A (zh) * 2019-11-01 2019-12-20 南京师范大学 阿糖胞苷4-n位氨基酸衍生物及其制备方法与应用
BR112022015429A2 (pt) * 2020-02-04 2022-09-27 Biosight Ltd Composições farmacêuticas de aspacitarabina e usos das mesmas
CN116234584A (zh) * 2020-09-21 2023-06-06 拜欧赛特有限公司 天冬阿糖胞苷的结晶形式
CN112409431B (zh) * 2020-12-07 2023-04-21 武汉伯瑞恒医药科技有限公司 阿糖胞苷结构类似物及其制备方法和用途
CA3239219A1 (en) * 2021-11-21 2023-05-25 Biosight Ltd. Cytarabine-amino acid based prodrug for the treatment of cancer
WO2023175622A1 (en) * 2022-03-17 2023-09-21 Biosight Ltd. Crystalline forms of aspacytarabine
WO2023228177A1 (en) * 2022-05-22 2023-11-30 Biosight Ltd. Compositions comprising aspacytarabine and additional compounds, and use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949451A (en) 1959-04-21 1960-08-16 Hoffmann La Roche Preparation of thymidine and deoxyfluorouridine, and intermediates therefor
US3041335A (en) 1959-04-21 1962-06-26 Hoffmann La Roche Mercury salts of nitrogen heterocyclics and preparation thereof
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4296105A (en) 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4348522A (en) 1980-01-23 1982-09-07 Starks Associates, Inc. N-(phosphonacetyl)-L-aspartic acid salts with piperazine, cyclohexylamine and calcium
EP0329184A3 (en) 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
FI105556B (fi) 1991-09-30 2000-09-15 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten pyrimidiiniukleosidijohdannaisten valmistamiseksi, joilla on kasvaimen vastaista vaikutusta
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1995018636A2 (en) 1994-01-11 1995-07-13 Targetech Inc Hepatocyte-targeted drug conjugates
DE69535665T2 (de) 1994-08-19 2009-04-02 La Region Wallonne Konjugate enthaltend ein antitumorales mittel und deren verwendung
JPH0859688A (ja) 1994-08-25 1996-03-05 Mitsui Toatsu Chem Inc ５’−チオノエステル置換トリフルオロチミジン誘導体およびそれを有効成分とする制癌剤
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
IL126318A (en) 1996-03-29 2004-09-27 Emisphere Tech Inc Compounds and compositions for delivering active agents and some novel carrier compounds
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
IL143666A0 (en) 1998-12-11 2002-04-21 Coulter Pharm Inc Prodrug compounds and process for preparation thereof
KR101115210B1 (ko) 2002-10-31 2012-04-12 메타베이시스 테라퓨틱스, 인크. 신규 시타라빈 모노포스페이트 전구약물
EP1718145A4 (en) 2004-02-02 2012-03-07 Biosight Ltd CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS
JP5410295B2 (ja) 2006-12-13 2014-02-05 ジボダン ネーデルランド サービシーズ ビー．ヴイ． カルボン酸およびプリン、ピリミジン、ヌクレオシドまたはヌクレオチドのフレーバー調節誘導体
CN101812105A (zh) 2009-02-25 2010-08-25 沈阳药科大学 阿糖胞苷5’-o-氨基酸酯和其盐类及其制备方法
JP5873656B2 (ja) * 2011-06-13 2016-03-01 株式会社Ihi 金属サレン錯体化合物、局所麻酔薬剤及び抗悪性腫瘍薬剤
TW201330845A (zh) 2011-10-18 2013-08-01 Ajinomoto Kk 胰臟癌及／或膽道癌治療劑
WO2014097318A2 (en) 2012-12-18 2014-06-26 Godavari Biorefineries Limited Agents for eliminating tumour-initiating cells
WO2015178265A1 (ja) 2014-05-23 2015-11-26 日本化薬株式会社 新規なグルタミン酸誘導体およびその用途

Also Published As

Publication number Publication date
US11058701B2 (en) 2021-07-13
AU2022204373B2 (en) 2024-01-25
AU2016362830B2 (en) 2022-07-14
JP2018535989A (ja) 2018-12-06
IL287644A (en) 2021-12-01
JP7149183B2 (ja) 2022-10-06
EP3383407A1 (en) 2018-10-10
AU2016362830A1 (en) 2018-07-12
IL259631A (en) 2018-07-31
WO2017093993A1 (en) 2017-06-08
JP2022097619A (ja) 2022-06-30
IL259631B (en) 2021-10-31
CA3007058C (en) 2023-10-17
CN108289905A (zh) 2018-07-17
JP2020183419A (ja) 2020-11-12
RU2708672C1 (ru) 2019-12-11
JP7417658B2 (ja) 2024-01-18
EP3383407A4 (en) 2019-07-17
US20180369265A1 (en) 2018-12-27
AU2022204373A1 (en) 2022-07-28
EP3383407B1 (en) 2023-12-06
CA3007058A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
BR112018011177A2 (pt) conjugados de citarabina para terapia de câncer
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
MX2019001517A (es) Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer.
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
JO3735B1 (ar) مركبات ألكين بها استبدال رباعي واستخداماتها
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
EA201590987A1 (ru) Соединения и способы их применения
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
BR112016024789A2 (pt) métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe
MX2019012464A (es) Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
EA201692100A1 (ru) Новые антитела против rnf43 и способы их применения
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
MX344772B (es) Analogos de estilbeno y metodos para tratar cancer.
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
BR112017022022A2 (pt) arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas)
CY1121749T1 (el) Προφαρμακα ανταγωνιστων nmda
EA201792560A1 (ru) Наночастицы для применения в качестве терапевтической вакцины
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]